HMNC Competitors and Similar CompaniesClear all
HMNC's competitors and similar companies include AgeneBio, NLS Pharmaceutics, Supernus Pharmaceuticals and Shionogi.
 HMNC HMNC is a biotechnology company that establishes personalized medicine in psychiatry and develops medications for depression and anxiety disorders. |  AgeneBio AgeneBio is a pharmaceutical company dedicated to developing therapeutics that prevent neurodegeneration, preserve and restore cognitive brain function. |  NLS Pharmaceutics NLS Pharmaceutics is a biopharmaceutical company engaged in drug discovery for central nervous system disorders. |  Supernus Pharmaceuticals Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. |  Shionogi Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases. | |
Founding Date | Founding Date 2010 | Founding Date 2008 | Founding Date 2019 | Founding Date 2005 | Founding Date 1878 |
Type | Type Private | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations München, DE HQ | Locations Baltimore, US HQ Baltimore, US | Locations Stans, CH HQ | Locations Rockville, US HQ | Locations Osaka, JP HQ Beijing, CN Hong Kong, HK Amagasaki, JP Amagasaki, JP Kanegasaki, JP Misato, JP see more |
Employees | Employees 3 | Employees 4 | Employees 6 | Employees 6527% increase | Employees 4,955 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 10.2 m | Valuation ($) 1.9 b | Valuation ($) 12.3 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $719m (FY, 2025) | Revenue (est.) ¥499.7b (FY, 2026) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $74.6m (FY, 2025) | Cost of goods ¥55.5b (FY, 2026) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $2.5m (FY, 2024) | Gross profit $644.4m (FY, 2025) | Gross profit ¥491.3b (FY, 2026) |
Net income | Net income N/A | Net income N/A | Net income ($2m) (FY, 2024) | Net income ($38.6m) (FY, 2025) | Net income ¥205.9b (FY, 2026) |
Operating ⚠ | |||||
Patents and Patent Applications | Patents and Patent Applications N/A | Patents and Patent Applications N/A | Patents and Patent Applications 5 (Feb, 2021) | Patents and Patent Applications N/A | Patents and Patent Applications 1.7 k (FY, 2018) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 9.5m | Total funding raised N/A | Total funding raised $ 69.5m | Total funding raised $ 4.7m |
For sources of this data, please see the company profile
View Company Profiles
AgeneBio
HQ
Baltimore, US
Employees
4
AgeneBio is a pharmaceutical company dedicated to developing therapeutics that prevent neurodegeneration, preserve and restore cognitive brain function.
View companyNLS Pharmaceutics
HQ
Stans, CH
Employees
6
NLS Pharmaceutics is a biopharmaceutical company engaged in drug discovery for central nervous system disorders.
View companySupernus Pharmaceuticals
HQ
Rockville, US
Employees
652↑ 7% increase
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders.
View companyShionogi
HQ
Osaka, JP
Employees
4,955
Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases.
View company